Arcus anti-TIGIT antibody differentiated from Roche’s, says …

Nov 27, 2024 · Barclays believes TIGIT "remains a show-me story at this point" and keeps an Overweight rating on Arcus with a $29 price target. The Arcus anti-TIGIT molecule is also …

$29
OFF

Arcus Anti-TIGIT Antibody Differentiated From Roche’s, Says …

2 weeks from now

Nov 27, 2024 · Barclays believes TIGIT "remains a show-me story at this point" and keeps an Overweight rating on Arcus with a $29 price target. The Arcus anti-TIGIT molecule is also …

nasdaq.com

5%
OFF

Barclays Keeps Their Buy Rating On Arcus Biosciences (RCUS)

2 weeks from now

1 day ago · Arcus anti-TIGIT antibody differentiated from Roche’s, says Barclays; Arcus Biosciences rises 10.5%; SHARE THIS POST. FACEBOOK. TWITTER. EMAIL. COPY LINK. …

businessinsider.com

5%
OFF

Bank Of America Securities Keeps Their Hold Rating On Arcus …

2 weeks from now

1 day ago · Arcus anti-TIGIT antibody differentiated from Roche’s, says Barclays; Arcus Biosciences rises 10.5%; SHARE THIS POST. FACEBOOK. TWITTER. EMAIL. COPY LINK. …

businessinsider.com

$29
OFF

Arcus Anti-TIGIT Antibody Differentiated From Roche’s, Says …

2 weeks from now

Nov 27, 2024 · Barclays believes TIGIT “remains a show-me story at this point” and keeps an Overweight rating on Arcus with a $29 price target. The Arcus anti-TIGIT molecule is also …

businessinsider.com

CHF 230
OFF

Roche Price Target Raised To CHF 230 From CHF 220 At JPMorgan

2 weeks from now

Dec 3, 2024 · Arcus anti-TIGIT antibody differentiated from Roche’s, says Barclays Poseida Therapeutics (NASDAQ:PSTX) Stock Skyrockets on News of Roche Holdings Acquisition …

nasdaq.com

$29
OFF

Hold Rating For Arcus Biosciences Amid Uncertainty And …

2 weeks from now

Nov 6, 2024 · Arcus Biosciences price target raised to $29 from $25 at Barclays; Arcus Biosciences Reports Promising Trial Results ... Arcus anti-TIGIT antibody differentiated from …

businessinsider.com

$25.00
OFF

Barclays Issues A Buy Rating On Arcus Biosciences (RCUS)

2 weeks from now

Oct 17, 2024 · Barclays analyst Peter Lawson assigned a Buy rating to Arcus Biosciences (RCUS – Research Report) today and set a price target of $25.00.The company’s shares closed …

businessinsider.com

FAQs about Arcus anti-TIGIT antibody differentiated from Roche’s, says … Coupon?

Should Barclays buy TIGIT (TIGIT)?

Barclays believes TIGIT “remains a show-me story at this point” and keeps an Overweight rating on Arcus with a $29 price target. The Arcus anti-TIGIT molecule is also differentiated from Roche’s tiragolumab given use of Fc-inactive domain for its anti-TIGIT antibody which could enable better safety and tolerability, the firm adds. ...

What is Arcus anti-TIGIT molecule?

The Arcus anti-TIGIT molecule is also differentiated from Roche’s tiragolumab given use of Fc-inactive domain for its anti-TIGIT antibody which could enable better safety and tolerability, the firm adds. Unlock your investing potential with TipRanks Premium - Now At 40% OFF! ...

Is roche's'sky-01' failure a negative read-through for anti-TIGIT space?

Barclays says Roche’s (RHHBY) SKY-01 failure is not totally unexpected but likely to be seen as a negative read-through for anti-TIGIT space. However, for Arcus Biosciences (RCUS), low expectations for its anti-TIGIT in lung cancer is likely already priced into the stock, the analyst tells investors in a research note. ...

Should you buy Arcus Biosciences (RCUS)?

Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $48.17. RCUS market cap is currently $1.26B and has a P/E ratio of -4.38. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. ...

Is Roche's (rhhby) sky-01 failure a negative read-through for anti-TIGIT space?

Barclays says Roche’s (RHHBY) SKY-01 failure is not totally unexpected but likely to be seen as a negative read-through for anti-TIGIT space. Ho... ...

How did Arcus Biosciences perform compared to last year?

Based on Arcus Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $48 million and a GAAP net loss of $92 million. In comparison, last year the company earned a revenue of $32 million and had a GAAP net loss of $71 million ...